201 related articles for article (PubMed ID: 37532471)
1. Leflunomide/hydroxychloroquine combination therapy targets type I IFN-associated proteins in patients with Sjögren's syndrome that show potential to predict and monitor clinical response.
Hamkour S; van der Heijden EH; Lopes AP; Blokland SLM; Bekker CPJ; Van Helden-Meeuwsen CG; Versnel MA; Kruize AA; Radstake TR; Leavis HL; Hillen MR; van Roon JA
RMD Open; 2023 Aug; 9(3):. PubMed ID: 37532471
[TBL] [Abstract][Full Text] [Related]
2. Additive immunosuppressive effect of leflunomide and hydroxychloroquine supports rationale for combination therapy for Sjögren's syndrome.
van der Heijden EH; Hartgring SA; Kruize AA; Radstake TR; van Roon JA
Expert Rev Clin Immunol; 2019 Jul; 15(7):801-808. PubMed ID: 31192747
[No Abstract] [Full Text] [Related]
3. Hydroxychloroquine treatment downregulates systemic interferon activation in primary Sjögren's syndrome in the JOQUER randomized trial.
Bodewes ILA; Gottenberg JE; van Helden-Meeuwsen CG; Mariette X; Versnel MA
Rheumatology (Oxford); 2020 Jan; 59(1):107-111. PubMed ID: 31237947
[TBL] [Abstract][Full Text] [Related]
4. MxA as a clinically applicable biomarker for identifying systemic interferon type I in primary Sjogren's syndrome.
Maria NI; Brkic Z; Waris M; van Helden-Meeuwsen CG; Heezen K; van de Merwe JP; van Daele PL; Dalm VA; Drexhage HA; Versnel MA
Ann Rheum Dis; 2014 Jun; 73(6):1052-9. PubMed ID: 23831963
[TBL] [Abstract][Full Text] [Related]
5. Revisiting the JOQUER trial: stratification of primary Sjögren's syndrome and the clinical and interferon response to hydroxychloroquine.
Collins A; Lendrem D; Wason J; Tarn J; Howard-Tripp N; Bodewes I; Versnel MA; Gottenberg JE; Seror R; Mariette X; Ng WF
Rheumatol Int; 2021 Sep; 41(9):1593-1600. PubMed ID: 34165604
[TBL] [Abstract][Full Text] [Related]
6. Is hydroxychloroquine effective in treating primary Sjogren's syndrome: a systematic review and meta-analysis.
Wang SQ; Zhang LW; Wei P; Hua H
BMC Musculoskelet Disord; 2017 May; 18(1):186. PubMed ID: 28499370
[TBL] [Abstract][Full Text] [Related]
7. Leflunomide-hydroxychloroquine combination therapy in patients with primary Sjögren's syndrome (RepurpSS-I): a placebo-controlled, double-blinded, randomised clinical trial.
van der Heijden EHM; Blokland SLM; Hillen MR; Lopes APP; van Vliet-Moret FM; Rosenberg AJWP; Janssen NG; Welsing PMJ; Iannizzotto V; Tao W; Pandit A; Barone F; Kruize AA; Radstake TRDJ; van Roon JAG
Lancet Rheumatol; 2020 May; 2(5):e260-e269. PubMed ID: 38273473
[TBL] [Abstract][Full Text] [Related]
8. Safety and Efficacy of Oral Hydroxychloroquine in the Treatment of Ophthalmic Disease Associated with Sjögren's Syndrome.
Fang W; Qingqing Z; Qihui L; Bing Z; Xinyue H; Jie X
Altern Ther Health Med; 2023 Nov; 29(8):656-662. PubMed ID: 37678871
[TBL] [Abstract][Full Text] [Related]
9. Primary Sjögren's syndrome: Extraglandular manifestations and hydroxychloroquine therapy.
Demarchi J; Papasidero S; Medina MA; Klajn D; Chaparro Del Moral R; Rillo O; Martiré V; Crespo G; Secco A; Catalan Pellet A; Amitrano C; Crow C; Asnal C; Pucci P; Caeiro F; Benzanquen N; Pirola JP; Mayer M; Zazzetti F; Velez S; Barreira J; Tamborenea N; Santiago L; Raiti L
Clin Rheumatol; 2017 Nov; 36(11):2455-2460. PubMed ID: 28913747
[TBL] [Abstract][Full Text] [Related]
10. Effect of Hydroxychloroquine Treatment on Dry Eyes in Subjects with Primary Sjögren's Syndrome: a Double-Blind Randomized Control Study.
Yoon CH; Lee HJ; Lee EY; Lee EB; Lee WW; Kim MK; Wee WR
J Korean Med Sci; 2016 Jul; 31(7):1127-35. PubMed ID: 27366013
[TBL] [Abstract][Full Text] [Related]
11. Clinical efficacy of leflunomide in primary Sjogren's syndrome is associated with regulation of T-cell activity and upregulation of IL-7 receptor α expression.
Bikker A; van Woerkom JM; Kruize AA; van der Wurff-Jacobs KM; Bijlsma JW; Lafeber FP; van Roon JA
Ann Rheum Dis; 2012 Dec; 71(12):1934-41. PubMed ID: 22563027
[TBL] [Abstract][Full Text] [Related]
12. In patients with primary Sjögren's syndrome innate-like MAIT cells display upregulated IL-7R, IFN-γ, and IL-21 expression and have increased proportions of CCR9 and CXCR5-expressing cells.
Hinrichs AC; Kruize AA; Leavis HL; van Roon JAG
Front Immunol; 2022; 13():1017157. PubMed ID: 36505431
[TBL] [Abstract][Full Text] [Related]
13. Long-term hydroxychloroquine therapy improves the quality of sleep in patients with primary Sjögren's syndrome: a real-world study.
Guan P; Sun C; Chen Z; Chen J; Ran R
Ann Palliat Med; 2020 Jul; 9(4):2203-2210. PubMed ID: 32692242
[TBL] [Abstract][Full Text] [Related]
14. A multi-center, open-label, randomized study to explore efficacy and safety of baricitinib in active primary Sjogren's syndrome patients.
Bai W; Yang F; Xu H; Wei W; Li H; Zhang L; Zhao Y; Shi X; Zhang Y; Zeng X; Leng X
Trials; 2023 Feb; 24(1):112. PubMed ID: 36793118
[TBL] [Abstract][Full Text] [Related]
15. Assessment of hydroxychloroquine blood levels in Sjögren's disease patients: drug adherence and clinical associations.
Pasoto SG; Villamarín LEB; de Vinci Kanda Kupa L; Deveza GBH; Ribeiro CT; Emi Aikawa N; Leon EP; de Oliveira Martins VA; Silva CA; Bonfa E
Rheumatol Int; 2024 Jul; 44(7):1305-1315. PubMed ID: 38294544
[TBL] [Abstract][Full Text] [Related]
16. Blood and salivary-gland BAFF-driven B-cell hyperactivity is associated to rituximab inefficacy in primary Sjögren's syndrome.
Cornec D; Costa S; Devauchelle-Pensec V; Jousse-Joulin S; Marcorelles P; Berthelot JM; Chiche L; Hachulla E; Hatron PY; Goeb V; Vittecoq O; Saraux A; Pers JO
J Autoimmun; 2016 Feb; 67():102-110. PubMed ID: 26688003
[TBL] [Abstract][Full Text] [Related]
17. Hydroxychloroquine improves dry eye symptoms of patients with primary Sjogren's syndrome.
Yavuz S; Asfuroğlu E; Bicakcigil M; Toker E
Rheumatol Int; 2011 Aug; 31(8):1045-9. PubMed ID: 20309693
[TBL] [Abstract][Full Text] [Related]
18. Increased CD200 levels in peripheral blood mononuclear cells of patients with primary Sjögren's syndrome.
Liu TT; Zeng XP; Gu ML; Deng AM
Int J Rheum Dis; 2020 May; 23(5):654-660. PubMed ID: 32180363
[TBL] [Abstract][Full Text] [Related]
19. The association between hydroxychloroquine use and future development of systemic lupus erythematosus in patients with primary Sjögren's syndrome.
Hsu BC; Chen YH; Lin CH; Tang KT
Int J Rheum Dis; 2022 Dec; 25(12):1424-1430. PubMed ID: 36089698
[TBL] [Abstract][Full Text] [Related]
20. Combined use of total glucosides of paeony and hydroxychloroquine in primary Sjögren's syndrome: A systematic review.
Zhang A; Chen S; Lin R
Immun Inflamm Dis; 2023 Oct; 11(10):e1044. PubMed ID: 37904705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
